These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 187107)

  • 1. Cellular immunology.
    Owen JJ
    Ann Clin Biochem; 1976 Sep; 13(5):485-7. PubMed ID: 187107
    [No Abstract]   [Full Text] [Related]  

  • 2. Antigenic specificity of cell-mediated antitumor reaction in the MSV system.
    Leclerc JC; Gomard E; Levy JP; Senik A
    Bibl Haematol; 1975 Oct; (43):173-6. PubMed ID: 60997
    [No Abstract]   [Full Text] [Related]  

  • 3. The murine sarcoma virus-induced tumor: exception or general model in tumor immunology?
    Levy JP; Leclerc JC
    Adv Cancer Res; 1977; 24():1-66. PubMed ID: 66859
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization to effector lymphocytes associated with immunity to murine sarcoma virus (MSV)-induced tumors. II. Repeated stimulation and proliferation in vitro of specific cytolytic T lymphocytes.
    Plata F; Jongeneel CV
    J Immunol; 1977 Aug; 119(2):623-9. PubMed ID: 196025
    [No Abstract]   [Full Text] [Related]  

  • 5. Isolation of malignant and functional Ly 1+ T-cell clones from B-cell lymphomas.
    Reinisch CL; Sing AP; Waldron JA; Kemp JD
    Nature; 1982 Jul; 298(5870):176-8. PubMed ID: 6283376
    [No Abstract]   [Full Text] [Related]  

  • 6. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. II. Analysis of the clonal progeny of CTL precursors stimulated in vitro with syngeneic tumor cells.
    Brunner KT; MacDonald HR; Cerottini JC
    J Immunol; 1980 Apr; 124(4):1627-34. PubMed ID: 6154076
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
    Cerundolo V; Lahaye T; Horvath C; Zanovello P; Collavo D; Engers HD
    Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of escape from immune surveillance.
    Klein G
    Natl Cancer Inst Monogr; 1976 Nov; 44():135-6. PubMed ID: 193018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell-mediated immunity to oncornavirus-induced tumors. I. Ly phenotype of precursor and effector cytolytic T lymphocytes.
    Leclerc JC; Cantor H
    J Immunol; 1980 Feb; 124(2):846-50. PubMed ID: 6243332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rejection of non viral tumors caused by infection with murine sarcoma virus].
    Basombrio MA
    Medicina (B Aires); 1977; 37(2):127-32. PubMed ID: 197370
    [No Abstract]   [Full Text] [Related]  

  • 11. Leukocyte adherence inhibition response to murine sarcoma virus-induced tumors. I. Cell requirements, specificity, lack of H-2 restriction, and role of antibody.
    Mortensen RF; Elson LM
    J Immunol; 1980 May; 124(5):2316-23. PubMed ID: 6154099
    [No Abstract]   [Full Text] [Related]  

  • 12. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
    Plata F; Jongeneel V; Cerottini JC; Brunner KT
    Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro interactions between tumor cells and immune lymphoid cells.
    Levy JP; Gomard E; Senik A; Leclerc JC
    Recent Results Cancer Res; 1976; (56):24-30. PubMed ID: 188084
    [No Abstract]   [Full Text] [Related]  

  • 14. The induction of immunoblastic T cell sarcomas by virus-transformed prothymocytes.
    Reinisch CL; Kurtz SE; Morris EA; Lampert A
    Am J Pathol; 1980 Nov; 101(2):265-82. PubMed ID: 6254363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo.
    Leclerc JC; Cantor H
    J Immunol; 1980 Feb; 124(2):851-4. PubMed ID: 6243333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell-dependent reactivity against tumor-associated antigens on allogeneic target cells.
    Holden HT; Landolfo S; Herberman RB
    Transplant Proc; 1977 Mar; 9(1):1149-52. PubMed ID: 194368
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of effector lymphocytes associated with immunity to murine sarcoma virus (MSV) induced tumors. I. Physical properties of cytolytic T lymphocytes generated in vitro and of their immediate progenitors.
    Plata R; MacDonald HR; Engers HD
    J Immunol; 1976 Jul; 117(1):52-8. PubMed ID: 180182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cytomegalovirus infection on the growth of murine fibrosarcomas--evidence for two separate host defense mechanisms against tumors.
    Lannin DR; Howard RJ; Yu S; Collins AL; McKhann CF
    Surg Forum; 1979; 30():145-7. PubMed ID: 231846
    [No Abstract]   [Full Text] [Related]  

  • 19. Induction of Moloney murine sarcoma virus tolerance in adult mice by anti-CD4 monoclonal antibody treatment.
    Biasi G; Mazzocchi M; Facchinetti A; Panozzo M; Zanovello P; Collavo D; Chieco-Bianchi L
    Cancer Res; 1990 Sep; 50(17 Suppl):5703S-5706S. PubMed ID: 2167167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Migration of null lymphocytes to murine sarcoma virus-induced tumors.
    Schwartz JL; Reinisch CL
    Clin Immunol Immunopathol; 1981 Jul; 20(1):74-86. PubMed ID: 6266725
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.